A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer

Yizhuo Xie; Zhihui Ren; Hongyu Chen; Huan Tang; Ming Zhu; Zhe Lv; Han Bao; Yan Zhang; Rui Liu; Yujia Shen; Yucui Zheng; Dongfanghui Miao; Xin Guo; Hongli Chen; Shanshan Wang; Jin Pei

doi:10.1016/j.biopha.2023.114304

A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer

Yizhuo Xie, Zhihui Ren, Hongyu Chen, Huan Tang, Ming Zhu, Zhe Lv, Han Bao, Yan Zhang, Rui Liu, Yujia Shen, Yucui Zheng, Dongfanghui Miao, Xin Guo, Hongli Chen, Shanshan Wang, Jin Pei^*

^*Corresponding author for this work

Jilin University

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Ovarian cancer is the second cause of death among gynecological malignancies. In this study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin and paclitaxel (ES-SSL-OXA/PTX) which could target estrogen receptor (ER) highly expressed on the surface of SKOV-3 cells to enhance therapeutic efficacy and reduce the side effects for SKOV-3 tumor therapy. ES-SSL-OXA/PTX was prepared by thin film hydration method and exhibited a uniform spherical morphology. Encapsulation efficiency (EE) were determined by HPLC method with the results of 44.10% for OXA and 65.85% for PTX. The mean particle size and polydispersity index (PDI) were 168.46 nm and 0.145, respectively. In vivo and in vitro targeting study confirmed that ES-SSL-OXA/PTX has optimum specific targeting ability. Meanwhile, In vitro and in vivo antitumor results of ES-SSL-OXA/PTX exhibited a superior antiproliferative effect on SKOV-3 cells and a stronger anti-tumor efficacy with the tumor inhibition rate of 85.24%. The pharmacokinetics results of ES-SSL-OXA/PTX showed a prolonged half-life time and a slowed clearance rate. The preliminary safety study of acute toxicity and long-term toxicity demonstrated ES-SSL-OXA/PTX exhibited a reduced toxicity profile. Based on the above results, ES-SSL-OXA/PTX could be a promising novel formulation for the treatment of ovarian cancer in future clinic.

Original language	English
Article number	114304
Journal	Biomedicine and Pharmacotherapy
Volume	160
DOIs	https://doi.org/10.1016/j.biopha.2023.114304
Publication status	Published - Apr 2023
Externally published	Yes

Keywords

Active targeting
Anti-tumor efficacy
Combined chemotherapy
Estrogen receptor
Liposome
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biopha.2023.114304

Cite this

Xie, Y., Ren, Z., Chen, H., Tang, H., Zhu, M., Lv, Z., Bao, H., Zhang, Y., Liu, R., Shen, Y., Zheng, Y., Miao, D., Guo, X., Chen, H., Wang, S., & Pei, J. (2023). A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer. Biomedicine and Pharmacotherapy, 160, Article 114304. https://doi.org/10.1016/j.biopha.2023.114304

@article{a0da7fabf2a24399be6ece9fa9558c02,

title = "A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer",

abstract = "Ovarian cancer is the second cause of death among gynecological malignancies. In this study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin and paclitaxel (ES-SSL-OXA/PTX) which could target estrogen receptor (ER) highly expressed on the surface of SKOV-3 cells to enhance therapeutic efficacy and reduce the side effects for SKOV-3 tumor therapy. ES-SSL-OXA/PTX was prepared by thin film hydration method and exhibited a uniform spherical morphology. Encapsulation efficiency (EE) were determined by HPLC method with the results of 44.10% for OXA and 65.85% for PTX. The mean particle size and polydispersity index (PDI) were 168.46 nm and 0.145, respectively. In vivo and in vitro targeting study confirmed that ES-SSL-OXA/PTX has optimum specific targeting ability. Meanwhile, In vitro and in vivo antitumor results of ES-SSL-OXA/PTX exhibited a superior antiproliferative effect on SKOV-3 cells and a stronger anti-tumor efficacy with the tumor inhibition rate of 85.24%. The pharmacokinetics results of ES-SSL-OXA/PTX showed a prolonged half-life time and a slowed clearance rate. The preliminary safety study of acute toxicity and long-term toxicity demonstrated ES-SSL-OXA/PTX exhibited a reduced toxicity profile. Based on the above results, ES-SSL-OXA/PTX could be a promising novel formulation for the treatment of ovarian cancer in future clinic.",

keywords = "Active targeting, Anti-tumor efficacy, Combined chemotherapy, Estrogen receptor, Liposome, Ovarian cancer",

author = "Yizhuo Xie and Zhihui Ren and Hongyu Chen and Huan Tang and Ming Zhu and Zhe Lv and Han Bao and Yan Zhang and Rui Liu and Yujia Shen and Yucui Zheng and Dongfanghui Miao and Xin Guo and Hongli Chen and Shanshan Wang and Jin Pei",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = apr,

doi = "10.1016/j.biopha.2023.114304",

language = "English",

volume = "160",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson s.r.l.",

}

TY - JOUR

T1 - A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer

AU - Xie, Yizhuo

AU - Ren, Zhihui

AU - Chen, Hongyu

AU - Tang, Huan

AU - Zhu, Ming

AU - Lv, Zhe

AU - Bao, Han

AU - Zhang, Yan

AU - Liu, Rui

AU - Shen, Yujia

AU - Zheng, Yucui

AU - Miao, Dongfanghui

AU - Guo, Xin

AU - Chen, Hongli

AU - Wang, Shanshan

AU - Pei, Jin

PY - 2023/4

Y1 - 2023/4

N2 - Ovarian cancer is the second cause of death among gynecological malignancies. In this study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin and paclitaxel (ES-SSL-OXA/PTX) which could target estrogen receptor (ER) highly expressed on the surface of SKOV-3 cells to enhance therapeutic efficacy and reduce the side effects for SKOV-3 tumor therapy. ES-SSL-OXA/PTX was prepared by thin film hydration method and exhibited a uniform spherical morphology. Encapsulation efficiency (EE) were determined by HPLC method with the results of 44.10% for OXA and 65.85% for PTX. The mean particle size and polydispersity index (PDI) were 168.46 nm and 0.145, respectively. In vivo and in vitro targeting study confirmed that ES-SSL-OXA/PTX has optimum specific targeting ability. Meanwhile, In vitro and in vivo antitumor results of ES-SSL-OXA/PTX exhibited a superior antiproliferative effect on SKOV-3 cells and a stronger anti-tumor efficacy with the tumor inhibition rate of 85.24%. The pharmacokinetics results of ES-SSL-OXA/PTX showed a prolonged half-life time and a slowed clearance rate. The preliminary safety study of acute toxicity and long-term toxicity demonstrated ES-SSL-OXA/PTX exhibited a reduced toxicity profile. Based on the above results, ES-SSL-OXA/PTX could be a promising novel formulation for the treatment of ovarian cancer in future clinic.

AB - Ovarian cancer is the second cause of death among gynecological malignancies. In this study, we designed a novel estrogen-targeted PEGylated liposome loaded with oxaliplatin and paclitaxel (ES-SSL-OXA/PTX) which could target estrogen receptor (ER) highly expressed on the surface of SKOV-3 cells to enhance therapeutic efficacy and reduce the side effects for SKOV-3 tumor therapy. ES-SSL-OXA/PTX was prepared by thin film hydration method and exhibited a uniform spherical morphology. Encapsulation efficiency (EE) were determined by HPLC method with the results of 44.10% for OXA and 65.85% for PTX. The mean particle size and polydispersity index (PDI) were 168.46 nm and 0.145, respectively. In vivo and in vitro targeting study confirmed that ES-SSL-OXA/PTX has optimum specific targeting ability. Meanwhile, In vitro and in vivo antitumor results of ES-SSL-OXA/PTX exhibited a superior antiproliferative effect on SKOV-3 cells and a stronger anti-tumor efficacy with the tumor inhibition rate of 85.24%. The pharmacokinetics results of ES-SSL-OXA/PTX showed a prolonged half-life time and a slowed clearance rate. The preliminary safety study of acute toxicity and long-term toxicity demonstrated ES-SSL-OXA/PTX exhibited a reduced toxicity profile. Based on the above results, ES-SSL-OXA/PTX could be a promising novel formulation for the treatment of ovarian cancer in future clinic.

KW - Active targeting

KW - Anti-tumor efficacy

KW - Combined chemotherapy

KW - Estrogen receptor

KW - Liposome

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85147219918&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2023.114304

DO - 10.1016/j.biopha.2023.114304

M3 - Article

C2 - 36724638

AN - SCOPUS:85147219918

SN - 0753-3322

VL - 160

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 114304

ER -

A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this